HALE ASLAN, Yılmaz ÖZKUL, ERCAN PINAR, Elif IŞIK, İBRAHİM ALADAĞ, ABDÜLKADİR İMRE, Murat SONGU, Demet ETİT

Oral kavite ve orofarengeal skuamöz hücreli kanserlerinde p16 pozitifliğinin etkisi

Amaç: Çalışmanın amacı oral kavite ve orofarengeal skuamöz hücreli karsinom (OK/OF SHK) hastalarında p-16 pozitifliğinin sıklığınıbelirlemek ve klinikopatolojik parametreler açısından p-16 pozitif vep-16 negatif olgular arasındaki farklılığı ortaya koymaktır. Yöntem:2007 ila 2015 yılları arasında ameliyat edilmiş yassı epitelhücreli 60 OK/OF SHK hastasının biyopsilerinde immünohistokimyasal yöntemle p16 antikoru analiz edilmiştir. p16 pozitif ve p16 negatif hastalar yaş, cinsiyet, sigara içimi, alkol kullanımı, tümör yeri,keratinizasyon düzeyi, T evresi, lenfovasküler invazyon, perinöral invazyon, tümör nüksü ve retrospektif olarak sağkalım açısından karşılaştırılmışlardır. Bulgular:Altmış hastanın (18 kadın, 42 erkek) ortanca yaşı 58 (aralık:27-75) idi. On yedi hasta p16 pozitif ve 43 hasta p16 negatif idi. Yaş,cinsiyet, T evresi, tümör yerleşimi, tümör derinliği, lenfovasküler veperinöral invazyon, ve sağkalım açısından gruplar arasında istatistiksel olarak anlamlı bir farklılık bulunmamaktaydı (p>0.05). Tümörnüksü, sigara içimi, ve keratinizasyonun derecesi açısından iki gruparasında istatistiksel farklılık mevcuttu. Sonuç:Oral kavite ve orofarengeal skuamöz hücreli karsinom tanısıalarak cerrahi olarak tedavi edilen hastalarda p16 pozitifliği tümörnüksü açısından prediktif bir parametredir.

Effect of p16 positivity in oral cavity and oropharyngeal squamous cell carcinoma

Objective:To determine the frequency of p16 positivity in oral cavity and oropharyngeal squamous cell carcinoma (OC/OP-SCC) andto reveal whether there is a difference between p16-positive and -negative cases according to clinicopathological parameters. Methods:p16 antibody was retrospectively analyzed immunohistochemically in biopsies of 60 patients with OC/OP-SCC operatedbetween 2007 to 2015. Comparison was performed for age, sex,smoking habit, alcohol consumption, site of the tumor, the level ofkeratinization, T stage, lymphovascular invasion, perineural invasion,recurrence of the tumor, and survival. Results: Of the 60 patients (18 females, 42 males), the median was 58(range: 27 to 75) years. Seventeen patients were p16-positive, and 43patients were p16-negative. Comparison of p16-positive and p16negative groups according to age, sex, T-stage, tumor subsite, tumorprofundity, lymphovascular invasion, perineural invasion and survivalwas not statistically significant (p>0.05). We found statistical difference between two groups according to tumor recurrence, smokinghabit, and the degree of keratinization. Conclusion:In patients who underwent surgical treatment after thediagnosis of zOC/OP-SCC, p16 positivity may have a predictive role interms of tumor recurrence.

PDF

___

1. Chandarana S, Lee J, Chanowski E, et al. Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer. Head Neck 2013; 35:1083-90.
2. Lewis J, Thorstad W, Chernock R, Haughey B, Yip J, Zhang Q, et al. p16 positive oropharyngeal squamous cell carcinoma:an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol 2010;34:1088-96.
3. Frisch M, Hjalgrim H, Jaeger AB, Biggar RJ. Changing patterns of tonsillar squamous cell carcinoma in the United States. Cancer Causes Control 2000;11:489-95.
4. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cellcycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
5. Rocco JW, Sidransky D. p16 (MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001;264:42-55.
6. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56:3630-3.
7. Ralli M, Singh S, Yadav S, Sharma N, Verma R, Sen R. Assessment and clinicopathological correlation of p16 expression in head and neck squamous cell carcinoma. J Cancer Res Ther 2016;12:232-7.
8. Smith EM, Rubenstein LM, Hoffman H, Haugen TH, Turek LP. Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer. Infect Agent Cancer 2010; 5:4.
9. Lazarus P, Sheikh SN, Ren Q, Schantz SP, Sten JC, Richie JP, et al. p53, but not p16 mutations in oral squamous cell carcinomas are associated with specific CYP1A1, and GSTM1 polymorphic genotypes and patient tobacco use. Carcinogenesis 1998;19:509-14.
10. Pintos J, Black MJ, Sadeghi N, Ghadirian P, Zeitoini AG, Viscidi RP et al. Human papillomavirus infection and oral cancer: a case control study in Montreal, Canada. Oral Oncol 2008;44:242-50.
11. Iyer N, Dogan S, Palmer F, Rahmati R, Nixon I, Lee N, et al. Detailed analysis of clinicopathologic factors demonstrate distinct difference in outcome and prognostic factors between surgically treated HPV-positive and negative oropharyngeal cancer. Ann Surg Oncol 2015;22:4411-21.
12. Lee LA, Huang C, Liao C, Lee LY, Hsueh C, Chen TC, et al. Human papillomavirus-16 infection in advanced oral cavity cancer patients is related to an increased risk of distant metastases and poor survival. Plos One 2012;7:1-11.
13. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612-9.